Aravive is focused on developing transformative, targeted, and innovative therapies to address the unmet medical needs of cancer patients.
Aravive’s principal place of business is in Houston, Texas, where it relocated after receiving a $20 million Product Development Award from the Cancer Prevention & Research Institute of Texas (CPRIT) in 2016.
AVB-500, our lead product candidate, is an ultra-high affinity decoy protein that targets the GAS6/AXL signaling pathway. By capturing circulating and bound GAS6, AVB-500 starves the AXL pathway of its signal, potentially halting the biological programming that promotes disease progression.
In preclinical studies, AVB-500 has been shown to suppress serum GAS6 to undetectable levels thereby stopping disease progression. AVB-500’s impressive safety and tolerability profile suggests it could be ideal for use in combination or as a maintenance therapy. Our proprietary biomarker is supporting development of AVB-500 in multiple oncology indications where GAS6/AXL signaling has been implicated.
Aravive is based in Houston, Texas, where it relocated after receiving a $20 million Product Development Award from the Cancer Prevention & Research Institute of Texas (CPRIT) in 2016.
